[News] CAR T-cells for relapsed B-cell ALL in children and young adults

Results of a phase 2 single-cohort clinical trial show that the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel provides durable remission with long-term persistence in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.

Source: The Lancet Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Robert Stirrups Tags: News Source Type: research